Використання методів діалізної терапії у дітей з гострою та хронічною нирковою недостатністю, гострим отруєнням речовинами нефротоксичної дії адаптована клінічна настанова, заснована на доказах Третинна медична допомога
жүктеу/скачать 1.37 Mb.
|
Gibson TP, Briggs WA, Boone BJ. Delivery of di-2-ethylhexyl phthalate to patients during hemodialysis. J Lab Clin Med 1976; 87: 519–524 (B) Gokal R, Alexander S, Ash S, et al. Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 update. (Official report from the International Society for Peritoneal Dialysis). Perit Dial Int 1998;18:11-33. Goldberg IJ, Kaufman AM, Lavarias VA, Vanni-Reyes T, Levin NW. High flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease. Nephrol Dial Transplant 1996; 11 [Suppl 2]: 104–107 (A) Gotch F, Sargent J. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985;28:526-534. Gutierrez A, Alvestrand A, Wahren J, Bergstro¨m J. Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 1990; 38: 487–494 (B) Gutierrez A, Bergstro¨m J, Alvestrand A. Protein catabolism in sham-hemodialysis: the effect of different membranes. Clin Nephrol 1992; 38: 22–29 (B) Gutierrez A. Protein catabolism in maintenance haemodialysis: the influence of the dialysis membrane. Nephrol Dial Transplant 1996; 11 [Suppl 2]: 108–111 (C) Haag-Weber M, Deppisch R, Go¨hl H, Ho¨ rl WH. Studies of biocompatibility of different dialyzer membranes: role of complement system, intracellular calcium and inositoltriphosphate. Clin Nephrol 1994; 41: 245–251 (B) Haeffner-Cavaillon N, Cavaillon JM, Cianconi C et al. In vivo induction of interleukin-1 during hemodialysis. Kidney Int 1989; 35: 1212–1218 (B) Haemodialysis Adequacy Work Group. NKF-DOQI clinical practice guidelines for haemodialysis adequacy, 2000 update. Am J Kidney Dis 2001; 37: S15–S55 (C) Hakim R, Fearon D, Lazarus J. Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int 1984; 26:194-200. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23: 661–669 (B) Hakim RM, Levin NW. Malnutrition in hemodialysis patients. Am J Kidney Dis 1993; 21: 125–137 (C) Held PJ, Port FK, Wolfe RA et al. The dose of haemodialysis and patient mortality. Kidney Int 1996; 50: 550–556 (B) Henle T, Deppisch R, Beck W et al. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 1999; 14: 1968–1975 (B) Herbelin A, Nguyen AT, Urena P, Descamps-Latscha B. Induction of cytokines by dialysis membranes in normal whole blood: a new in vitro assay for evaluating membrane biocompatibility. Blood Purif 1992; 10: 40–52 (B) Himmelfarb J, Ault KA, Holbrook D, Leeber DA, Hakim RM. Intradialytic granulocyte reactive oxygen species production: a prospective, crossover trial. J Am Soc Nephrol 1993; 4: 178–186 (B) Himmelfarb J, Hakim RM. Biocompatibility and risk of infection in haemodialysis patients. Nephrol Dial Transplant 1994; 9 [Suppl 2]: 138–144 (C) Himmelfarb J, Lazarus JM, Hakim R. Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 1991; 17: 271–276 (B) Himmelfarb J, MacMonagle E, Holbrook D, Toth C. Soluble complement receptor 1 inhibits both complement and granulocyte activation during ex vivo hemodialysis. J Lab Clin Med 1995; 126: 392–400 (B) Himmelfarb J, Zaoui P, Hakim R. Modulation of granulocyte LAM-1 and MAC-1 during dialysis—a prospective, randomized controlled trial. Kidney Int 1992; 41: 388–395 (B) Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869–876 Hoenich NA, Thompson J, Varini E, MacCabe J, Appleton D. Particle spallation and plasticiser (DEHP) release from extracorporeal circuit tubing materials. Int J Artif Organs 1990; 13: 55–62 (B) Hoenich NA, Woffindin C, Stamp S, Roberts SJ, Turnbull J.Synthetically modified cellulose: an alternative to synthetic membranes for use in haemodialysis? Biomaterials 1997; 18: 1299–1303 (B) Hoenich NA. Spallation and plasticizer release from hemodialysis blood tubing: a cause of concern? Semin Dial 1991; 4: 227–230 (C) Honkanen E, Gro¨nhagen-Riska C, Teppo AM, Maury CPJ, Meri S. Acute-phase proteins during hemodialysis: correlations with serum-1b levels and different dialysis membranes. Nephron 1991; 57: 283–287 (A) Horl WH, Haag-Weber M, Georgopoulos A, Block LH. Physicochemical characterization of a polypeptide present in uraemic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci USA 1990; 87: 6353–6357 (B) Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high- flux dialysis. J Am Soc Nephrol 1992; 3: 1227–1237 (B) Hornberger JC. The haemodialysis prescription and qualityadjusted life expectancy. Renal Physicians Association Working Committee on clinical guidelines. J Am Soc Nephrol 1993; 4: 1004 –1020 (C) Hou FF, Chertow GM, Kay J et al. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Kidney Int 1997; 51: 1514–1519 (B) Ikizler TA, Fkakoll PJ, Parker RA, Hakim RM. Amino acid and albumin losses during hemodialysis. Kidney Int 1994; 46: 830–837 (B) Ikizler TA, Greene JH, Yenicesu M, Schulman G, Wingard RL, Hakim RM: Nitrogen balance in hospitalized chronic hemodialysis patients. Kidney Int Suppl 57:S53-S56, 1996 Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 1999; 55: 1945–1951 (B) Jacobs AA, Ward RA, Wellhausen SR, MacLeish KR. Polymorphonuclear leukocyte function during hemodialysis: relationship to complement activation. Nephron 1989; 52: 119–124 (B) Jadoul M, Garbar C, Noe¨l H et al. Histological prevalence of b2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study. Kidney Int 1997; 51: 1928–1932 (B) Josephson MA, Fellner SK, Dasgupta A. Improved lipid profiles in patients undergoing high-flux haemodialysis. Am J Kidney Dis 1992; 20: 361–366 (B) Kabanda A, Jadoul M, Pochet JM et al. Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance haemodialysis. Kidney Int 1994; 45: 1689–1696 (B) Kaizu Y, Kimura M, Yoneyama T et al. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 1998; 31: 93–100 (B) Kaysen GA. Inflammation nutritional state and outcome in end stage renal disease. Miner Electrolyte Metab 1999; 25: 242–250 (C) Kielstein JT, Boger RH, Bode-Boger SM et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594–600 (B) Kirmani N, Tuazon CU, Murray HW, Parrish AE, Sheagren JN. Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis. Arch Intern Med 1978; 138: 1657–1659 (B) Koda Y, Nishi S, Miyazaki S et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52: 1096–1101 (B) Kuwahara T, Markert M, Wauters JP. Proteins adsorbed on hemodialysis membranes modulate neutrophil activation. Artif Organs 1989; 13: 427–431 (B) Leblanc M, Charbonneau R, Lalumiere G, Cartier P, Deziel C.Postdialysis urea rebound: determinants and influence on dialysis delivery in chronic haemodialysis patients. Am J Kidney Dis 1996; 27: 253–261 (B) Lewis LM, Flechtner TW, Kerkay J, Pearson KH, Nakamoto S. Bis(2-ethylhexyl)phthalate concentrations in the serum of hemodialysis patients. Clin Chem 1978; 24: 741–746 (B) Leypoldt JK, Cheung AK, Agodoa LY et al. Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. The Haemodialysis (HEMO) Study. Kidney Int 1997; 51: 2013–2017 (B) Lhotta K, Wu¨ rzner R, Kronenberg F, Oppermann M, Ko¨ nig P.Rapid activation of the complement system by cuprophane depends on complement component C4. Kidney Int 1998; 53: 1044–1051 (B) Lim VS, Bier DM, Flanigan MJ, Sum-Ping ST. The effect of hemodialysis on protein metabolism. A leucine kinetic study. J Clin Invest 1993; 91: 2429–2436 (B) Lin JL, Kou MT, Leu ML: Effect of long-term low-dose aluminum-containing agents on hemoglobin synthesis in patients with chronic renal insufficiency. Nephron 74:33-38, 1996 Locatelli F, Mastrangelo F, Raedelli B et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. Kidney Int 1996; 50: 1293–1302 (A) Lonnemann G, Koch KM, Shaldon S, Dinarello CA. Studies on the ability of haemodialysis membranes to induce, bind, and clear human interleukin-1. J Lab Clin Med 1988; 112:76–86 (B) Lowrie EG, Chertow GM, Lew NL, Lazarus JM, Owen WF. The urea [clearance3dialysis time] product (Kt) as an outcomebased measure of haemodialysis dose. Kidney Int 1999; 56: 729–737 (B) Lucchi L, Bonucchi D, Acerbi MA et al. Improved biocompatibility by modified cellulosic membranes: the case of hemophan. Artif Organs 1989; 13: 417–421 (B) Maduell F, Garcia-Valdecasas J, Garcia H et al. Validation of different methods to calculate KtV considering postdialysis rebound. Nephrol Dial Transplant 1997; 12: 1928–1933 (B) Maeda K, Shinzato T, Ota T et al. Beta-2-microglobulin generation rate and clearance rate in maintenance haemodialysis patients. Nephron 1990; 56: 118–125 (B) Marchant A, Tielemans C, Husson C et al. Cuprophane haemodialysis induces upregulation of LPS receptor (CD14) on monocytes: role of complement activation. Nephrol Dial Transplant 1996; 11: 657–662 (B) Marr KA, Kong L, Fowler VG et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients.Kidney Int 1998; 54: 1684–1689 (B) Martin-Malo A, Carracedo J, Ramirez R et al. Effect of uremia and dialysis modality on mononuclear cell apoptosis. J Am Soc Nephrol 2000; 11: 936–942 (B) Martin-Malo A, Castillo D, Castro M et al. Biocompatibility of dialysis membranes: a comparative study. Nephrol Dial Transplant 1991; 6 [Suppl 2]: 55–58 (B) Matsuoka H, Itoh S, Kimoto M et al. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997; 29: 242–247 (B) Memoli B, Postiglione L, Cianciaruso B et al. Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients. Kidney Int 2000; 58: 417–424 (B) Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 132: 391–402 (C) Miyata T, Hori O, Zhang J et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-b2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. J Clin Invest 1996; 98: 1088–1094 (B) Miyata T, Inagi R, Iida Y et al. Involvement of b2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 1994; 93: 521–528 (B) Miyata T, Ueda Y, Yoshida A et al. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 1997; 51: 880–887 (B) Miyata T, Wada Y, Cai Z et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997; 51: 1170–1181 (B) Moeslinger T, Friedl R, Volf I et al. Urea induces macrophage proliferation by inhibition of inducible nitric oxide synthesis. Kidney Int 1999; 56: 581–588 (B) Mordacchini M, Teodori T, Collodel L et al. Flow-cytometric study of granulocyte activation during hemodialysis with different membranes. Blood Purif 1995; 13: 322–326 (B) Morti SM, Zydney AL. Protein-membrane interactions during haemodialysis: effects on solute transport. ASAIO J 1998; 44: 319–326 (B) Neveceral P, Markert M, Wauters JP. Role of protein adsorption on haemodialysis-induced complement activation and neutrophil defects. Nephrol Dial Transplant 1995; 10: 372–376 (B) Nguyen AT, Lethias C, Zingraff J et al. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within micro amounts of whole blood. Kidney Int 1985; 28: 158–167 (B) Niwa T, Katsuzaki T, Miyazaki S et al. Amyloid b2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 1997; 51: 187–194 (B) Niwa T, Katsuzaki T, Momoi T et al. Modification of b2-m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 1996; 49: 861–867 (B) Odetti P, Cosso L, Pronzato MA, Dapino D, Gurreri G. Plasma advanced glycosylation end-products in maintenance haemodialysis patients. Nephrol Dial Transplant 1995;10: 2110–2113 (B) Opatrny K, Krouzecky A, Wirth J, Vit L, Eiselt J. The effects of a polyacrylonitrile membrane and a membrane made of regenerated cellulose on the plasma concentrations of erythropoietin during hemodialysis. Artif Organs 1998; 22: 816–820 (B) Owen WF Jr, Chertow GM, Lazarus JM, Lowrie EG. Dose of haemodialysis and survival: differences by race and sex. J Am Med Assoc 1998; 280: 1764–1768 (B) Parker TF III, Husni L, Huang W, Lew N, Lowrie EG. Survival of haemodialysis patients in the United States is improved with a greater quantity of dialysis. Am J Kidney Dis 1994; 23: 670–680 (B) Parker TF, Wingard RL, Husni L et al. Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Kidney Int 1996; 49: 551–556 (A) Pedrini LA, De Cristofano V, Pagliari B, Sama F. Mixed predilution and postdilution online haemodiafiltration compared with the traditional infusion modes. Kidney Int 2000; 58: 2155–2165 (B) Perkowski SZ, Havill AM, Flynn JT, Gee MH. Role of intrapulmonary release of eicosanoids and superoxide anion as mediators of pulmonary dysfunction and endothelial injury in sheep with intermittent complement activation. Circ Res 1983; 53: 574–583 (B) Pertosa G, Grandaliano G, Gesualdo L et al. Interleukin-6, interleukin-8 and monocyte chemotactic peptide-1 gene expression and protein synthesis are independently modulated by hemodialysis membranes. Kidney Int 1998; 54: 570–579 (B) Prabhakar SS, Zeballos GA, Montoya-Zavala M, Leonard C.Urea inhibits inducible nitric oxide synthase in macrophage cell line. Am J Physiol 1997; 273: C1882–C1888 (B) Priester-Coary A, Daugirdas JT. A recommended technique for obtaining the post-dialysis BUN. Semin Dial 1997; 10: 23–25 (C) Raad II, Hohn DC, Gilbreath BJ et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol 1994; 15: 231–238 (B) Ro¨ ckel A, Klinke B, Hertel J et al. Allergy to dialysis materials. Nephrol Dial Transplant 1989; 4: 646–652 (B) Robson MD, Charoenpanich R, Kant KS et al. Effect of first and subsequent use of hemodialyzers on patient well being. Analysis of the incidence of symptoms and events and description of a syndrome associated with new dialyzer use. Am J Nephrol 1986; 6: 101–106 (B) Roccatello D, Mazzucco G, Coppo R et al. Functional changes of monocytes due to dialysis membranes. Kidney Int 1989; 35: 622–631 (B) Ronco C, Brendolan A, Crepaldi C, La Greca G. Ultrafiltrations—rates und dialyse hypotension. Dialyse J 1992; 40: 8–15 (C) Ronco C, Heifetz A, Fox K et al. Beta 2-microglobulin removal by synthetic dialysis membranes. Mechanisms and kinetics of the molecule. Int J Artif Organs 1997; 20: 136–143 (B) Rosenkranz AR, Ko¨rmo¨ czi GF, Thalhammer F et al. Novel C5-dependent mechanism of neutrophil stimulation by bioincompatible dialyzer membranes. J Am Soc Nephrol 1999; 10: 128–135 (B) Rousseau Y, Carreno MP, Poignet JL, Kazatchkine MD, Haeffner-Cavaillon N. Dissociation between complement activation, integrin expression and neutropenia during hemodialysis. Biomaterials 1999; 20: 1959–1967 (B) Rysz J, Luciak M, Kedziora J, Blaszczyk J, Sibinska E. Nitric oxide release in the peripheral blood during hemodialysis. Kidney Int 1997; 51: 294–300 (B) Santoro A, Ferrari G, Francioso A et al. Ethylene-oxide and steam-sterilised polysulfone membrane in dialysis patients with eosinophilia. Int J Artif Organs 1996; 19: 329–335 (B) Sargent JA, Gotch FA. Mathematic modeling of dialysis therapy. Kidney Int 1980; 18 [Suppl 10]: S2–S10 (B) Sargent JA, Gotch FA. The analysis of concentration dependence of uraemic lesions in clinical studies. Kidney Int 1975;7 [Suppl 2]: S35–S44 (B) Schaefer F, Wuhl E, Haffner D, et al. Stimulation of growth by recombinant human growth hormone in children undergoing peritoneal or hemodialysis treatment. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Adv Perit Dial 1994;10:321-326. Schaefer RM, Rauterberg EW, Deppisch R, Vienken J.Assembly of terminal SC5b-9 complement complexes: a new index of blood-membrane interaction. Miner Electrolyte Metab 1990; 16: 73–76 (B) Schiller B, Ziegler-Heitbrock HWL, Meyer N, Schmidt B, Blumenstein M. Monocyte phenotype and interleukin-1 production in patients undergoing haemodialysis. Nephron 1991; 59: 573–579 (B) Schindler R, Boenisch O, Fischer C, Frei U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 2000; 53: 452–459 (A) Schindler R, Linnenweber S, Schulze M et al. Gene expression of interleukin-1 during hemodialysis. Kidney Int 1993; 43: 712–721 (B) Schindler R, Lonnemann G, Shaldon S, Koch KM, Dinarello CA. Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement. Kidney Int 1990; 37: 85–93 (B) Schroder M, Riedel E, Beck W, Deppisch RM, Pommer W. Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes.Kidney Int 2001; 59: 19–24 (B) Schulman G, Hakim R, Arias R et al. Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction. J Am Soc Nephrol 1993; 3: 1563–1569 (B) Smye SW, Dunderdale E, Brownridge G, Will E. Estimation of treatment dose in high-efficiency haemodialysis. Nephron 1994; 67: 24–29 (B) Smye SW, Tattersall JE, Will EJ. Modeling the postdialysis rebound: the reconciliation of current formulas. ASAIO J 1999; 45: 562–567 (B) Spiegel DM, Baker PL, Babcock S, Contiguglia R, Klein M. Haemodialysis urea rebound: the effect of increasing dialysis efficiency. Am J Kidney Dis 1995; 25: 26–29 (B) Strasser T, Schiffl H. Generation of leukotriene B4 by hemodialyzer membranes: a novel index of biocompatibility. Klin Wochenschr 1991; 69: 808–812 (B) Szepietowski T, Krajewska M. C-reactive protein (CRP) as a marker of of hemodialysis biocompatibility. Polim Med 1997; 27: 47–59 (B) Tayeb JS, Provenzano R, El Ghoroury M et al. Effect of biocompatibility of hemodialysis membranes on serum albumin levels. Am J Kidney Dis 2000; 35: 606–610 (B) Thorlacius H, Fernvik E, Gautam N et al. Impaired leucocyte rolling, adhesion and transendothelial migration following cuprophane hemodialysis. Acta Physiol Scand 1997; 159: 277–283 (B) Thylen P, Lundahl J, Fernvik E et al. Mobilization of an intracellular glycoprotein (Mac-1) on monocytes during hemodialysis. Am J Nephrol 1992; 12: 393–400 (B) Tielemans C, Delville JPC, Husson CP et al. Adhesion molecules and leukocyte common antigen on monocytes and granulocytes during hemodialysis. Clin Nephrol 1993; 39: 158–165 (B) Traeger J, Sibai-Galland R, Delawari E, Arkouche W. Daily versus standard haemodialysis: one year experience. Artif Organs 1998; 22: 558–563 (B) Tschesche H, Kopp C, Horl WH, Hempelmann U. Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment. J Biol Chem 1994; 269: 30274 –30280 (B) Van Tellingen A, Grooteman MP, Bartels PC et al. Long-term reduction of plasma homocysteine levels by super-flux dialyzers in haemodialysis patients. Kidney Int 2001; 59: 342–347 (B) Vanholder R, De Smet R. Pathophysiological effects of uraemic retention solutes. J Am Soc Nephrol 1999; 10: 1815–1823 (C) 41. Daugirdas JT. Simplified equations for monitoring KtuV, PCRn, eKtV, and ePCRn. Adv Ren Replace Ther 1995; 2: 295–304 (B) Vanholder R, Dell’Aquila R, Jacobs V et al. Depressed phagocytosis in hemodialyzed patients: in vivo and in vitro mechanisms. Nephron 1993; 63: 409–415 (B) Vanholder R, Ringoir S, Dhondt A, Hakim R. Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. Kidney Int 1991; 39: 320–327 (A) Vanholder RC, Pauwels RA, Vandenbogaerde J et al. Cuprophan reuse and intradialytic changes of lung diffusion capacity and blood gasses. Kidney Int 1987; 32: 117–122 (B) Ventura MT, Di Corato R, Giuliano G, Matino MG, Antonaci S. Evaluation of monocyte chemotactic responsiveness in uraemic patients undergoing haemodialysis with different dialytic membranes. Cytobios 1998; 96: 171–178 (B) Verresen L, Fink E, Lemke HD, Vanrenterghem Y. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int 1994; 45: 1497–1503 (B) Villaroel F, Ciarkowski A. A survey of hypersensitivity reactions in hemodialysis. Artif Organs 1985; 9: 231–238 (B) Ward RA, Schmidt B, Blumenstein M, Gurland HJ. Evaluation of phagocytic cell function in an ex vivo model of hemodialysis. Kidney Int 1990; 37: 776–782 (B) Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W.A comparison of on-line haemodiafiltration and high-flux haemodialysis: a prospective clinical study. J Am Soc Nephrol 2000; 11: 2344–2350 (A) Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 1980; 33: 27–39 (B) Woods JD, Port FK, Orzol S et al. Clinical and biochemical correlates of starting ‘daily’ haemodialysis. Kidney Int 1999; 55: 2467–2476 (B) Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469–476 (B) Yu VL, Goetz A, Wagener M et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986; 315: 91–96 (B) Zaoui P, Green W, Hakim RM. Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression. Kidney Int 1991; 39: 1020–1026 (B) Zaoui P, Hakim R. Natural killer-cell function in hemodialysis patients: effect of the dialysis membrane. Kidney Int 1993; 43: 1298–1305 (B) Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648–658 (B) Zingraff J, Beyne P, Urena P et al. Influence of haemodialysis membranes on b2-microglobulin kinetics: in vivo and in vitro studies. Nephrol Dial Transplant 1988; 3: 284–290 (B) жүктеу/скачать 1.37 Mb. Достарыңызбен бөлісу:
|